研究单位：[1]AnchorDx Medical Co., Ltd.[2]The First Affiliated Hospital of Guangzhou Medical University[3]Xiangya Hospital of Central South University[4]Tongji Hospital
AnchorDx is using circulating tumor DNA (ctDNA) methylation analysis by next-generation sequencing (NGS) to develop a blood-based assay for differentiating benign and malignant pulmonary nodules early. The purpose of this study is to evaluate the diagnostic performance of this assay in patients with pulmonary nodules.
